Navigation Links
VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
Date:4/20/2012

ts the view that VeriStrat may be useful in identifying lung cancer patients that could benefit from the combination of bevacizumab and erlotinib, which is regarded as less toxic than traditional chemotherapy."

About VeriStrat:  VeriStrat is a serum proteomic test currently available for patients with advanced NSCLC.  The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs).  Samples are processed in Biodesix' CLIA certified laboratory and results are typically reported within 72 hours of sample shipment.  VeriStrat has been validated in clinical studies with over 1500 patients.  For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix:  Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care.  The Company's goal is to give physicians more information about the patient and their disease; understanding the clinically meaningful information contained within each patient's molecular profile leads to better care and better outcomes. The Company's unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles. Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies. For more information about Biodesix, please visit www.Biodesix.com.

This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe
'/>"/>

SOURCE Biodesix
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
2. VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients
3. VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Cepheid Reports 2012 First Quarter Results
6. Amgen Announces Webcast of 2012 First Quarter Financial Results
7. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
8. Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2
9. Solta Medical to Report First Quarter 2012 Results Release and Host Conference Call on May 1
10. Valeant Pharmaceuticals to Announce 2012 First Quarter Results on May 3, 2012
11. Mastech Holdings, Inc. to Discuss First Quarter 2012 Financial Results on April 25, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... at the 34 th Annual Canaccord Genuity Growth Conference ... , on Wednesday, August 13 th at 4:30 ... available at http://ir.nxstage.com/ .  About NxStage ...
(Date:8/1/2014)... HYDERABAD, India , Aug. 1, 2014 /PRNewswire/ ... manufacturer providing active pharmaceutical ingredients (APIs), ... to customers located in 85 countries, today announced ... year (FY) 2015, ended June 30, 2014. ... affected by work flow re-prioritization to accommodate certain ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... April 29, 2011 Halozyme Therapeutics, Inc. (Nasdaq: ... products targeting the extracellular matrix , today announced ... on Friday, May 6, 2011 before the open of ... a conference call with the investment community at 8:00 ...
... SAN MATEO, Calif., April 29, 2011 ... patch purchased by 321 institutions, up from 239 in Q4 ... Qutenza product revenue Operational focus enables lower planned expense ... Czech Republic by Astellas NGX-1998 Phase 2 clinical trial ...
Cached Medicine Technology:Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 2NeurogesX Reports First Quarter 2011 Results 2NeurogesX Reports First Quarter 2011 Results 3NeurogesX Reports First Quarter 2011 Results 4NeurogesX Reports First Quarter 2011 Results 5NeurogesX Reports First Quarter 2011 Results 6NeurogesX Reports First Quarter 2011 Results 7NeurogesX Reports First Quarter 2011 Results 8
(Date:8/1/2014)... 2014 As AndroGel lawsuits and testosterone ... E. Johnson, Jr. has been appointed as co-lead counsel ... testosterone medications. Since the Fall of 2013, Ron and ... diligently to investigate and prosecute the claims of men ... clots as a result of taking testosterone. As a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
(Date:8/1/2014)... August 01, 2014 The "Antimicrobial ... such as Zinc Oxide, Titanium Dioxide, and Zinc ... & Construction, Food & Beverages, Textiles, and others), ... - Global Trends and Forecasts to 2018" analyzes ... drivers, opportunities, and trends in the diverse geographical ...
(Date:8/1/2014)... 2014 According to new market ... (Asia-Pacific, North America, Europe, & ROW), by Vehicle ... Type (Gasoline & Diesel), by After-Treatment Device (DPF, ... & Forecasts to 2019", defines and segments the ... of major countries in all the regions, and ...
(Date:8/1/2014)... NY August 1, 2014 The Cardiovascular ... and first report investigations that will be presented ... scientific symposium. TCT, the world,s premier educational meeting ... September 13 17, 2014 at the Walter ... Clinical research data presented at TCT often direct ...
Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4
... Preserves Competition for Medicare Advantage,Plans Sold to Senior ... of,Justice announced today that it will require UnitedHealth ... to divest assets relating,to United,s Medicare Advantage business ... with United,s acquisition of Sierra. The Department said ...
... An article co-authored by Susan L. Mitchell, M.D., ... reports that nursing home residents with advanced dementia ... two weeks before death. This practice raises concerns ... with advanced dementia, as well as the emergence ...
... place burden on Medicare, analysis finds , , MONDAY, Feb. ... Americans newly diagnosed with heart failure has declined, the ... new research finds. , The Duke University study analyzed ... diagnosed with heart failure between 1994 and 2003. It ...
... Combined hormone therapy appears to increase the risk that ... it may decrease the effectiveness of both methods for ... Feb. 25 issue of Archives of Internal Medicine, one ... Ph.D., a lead investigator at the Los Angeles Biomedical ...
... 20 percent of patients taking aspirin to lower the ... have an antiplatelet response from aspirin, the effect thought ... at Buffalo have shown. , Millions of people ... stroke, second heart attack or second episode of peripheral ...
... a Systems Biology company focussed on high quality annotation ... its abilities in the analysis of data generated by ... et al published in the January 2008 issue of ... Open Chromatin across the Genome where they identified DNase ...
Cached Medicine News:Health News:Justice Department Requires Divestiture in UnitedHealth Group's Acquisition of Sierra Health Services 2Health News:Justice Department Requires Divestiture in UnitedHealth Group's Acquisition of Sierra Health Services 3Health News:Hebrew SeniorLife researcher finds 2Health News:Hebrew SeniorLife researcher finds 3Health News:More Elderly Americans Living With Heart Failure 2Health News:LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies 2Health News:Many stroke, heart attack patients may not benefit from aspirin 2Health News:Many stroke, heart attack patients may not benefit from aspirin 3Health News:Genomatix integrates genome-wide open chromatin from next generation sequencing 2
POLYSORB™ sutures are composed of LACTOMER™ glycolide/lactide copolymer which is a synthetic polyester composed of glycolide and lactide (derived from glycolic and lactic acids)....
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO SLIDE™ single use knot pusher with 12 units per box....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: